Myosin IIIa Activators
Myosin IIIa activators are compounds that can influence MYO3A indirectly through different biochemical and cellular pathways. For instance, PIP2 is critical in the modulation of actin-binding proteins and thus can influence MYO3A's activity by altering its interaction with the actin cytoskeleton. Similarly, calcium-modulated proteins such as calmodulin can bind to MYO3A and induce conformational changes that may activate the motor protein. Additionally, modulation of second messenger systems such as cAMP via adenylate cyclase activators like forskolin, or cAMP analogs like 8-Bromo-cAMP, can activate PKA which in turn could phosphorylate and thus regulate MYO3A activity.
The manipulation of phosphorylation states through inhibitors of protein phosphatases like okadaic acid, or via the inhibition of GSK-3 by lithium chloride, demonstrates how altering the balance of protein phosphorylation can indirectly affect MYO3A activity. Compounds like PMA and bisindolylmaleimide I highlight the role of PKC in the phosphorylation of myosin light chains, a process that is critical for MYO3A's interaction with actin. The involvement of tyrosine kinase pathways is evident with the use of genistein and sodium orthovanadate, which modulate the phosphorylation status of proteins indirectly associated with MYO3A function. Lastly, essential ions like manganese are required for the activity of enzymes that produce signaling molecules influencing MYO3A's phosphorylation and motor activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Calmodulin (human), (recombinant) | 73298-54-1 | sc-471287 | 1 mg | $300.00 | ||
Calmodulin is a calcium-binding messenger protein. MYO3A has calmodulin-binding sites, indicating that upon binding to calcium-loaded calmodulin, its motor activity could be affected, leading to conformational changes that enhance its ATPase activity and subsequently its function in cells. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin directly activates adenylate cyclase, increasing the intracellular concentration of cAMP. Elevated cAMP levels can lead to activation of PKA, which can phosphorylate certain sites on MYO3A, possibly influencing its motor activity and interaction with actin filaments. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a diacylglycerol analog that activates protein kinase C (PKC). PKC has been implicated in the phosphorylation of myosin light chains, which could alter MYO3A function and its interaction with actin, thereby indirectly increasing its activity. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
Calcium ionophores increase intracellular calcium levels, which can bind to calmodulin. The calcium-calmodulin complex may then bind to MYO3A, influencing its motor function and actin-binding activity, leading to activation. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic acid is a potent inhibitor of protein phosphatases 1 and 2A, which prevents dephosphorylation of proteins. Persistent phosphorylation could result in sustained activation of MYO3A via phosphorylation sites that regulate its motor activity. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium influences several cellular signaling pathways, including the inhibition of glycogen synthase kinase-3 (GSK-3). Inhibition of GSK-3 could modify the phosphorylation state of proteins within the actin cytoskeleton pathway, which may affect MYO3A activity indirectly through changes in actin dynamics. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
8-Bromo-cAMP is a cell-permeable cAMP analog that activates PKA. PKA can phosphorylate myosin light chain kinase, leading to changes in myosin-actin interactions, which could indirectly influence MYO3A activity by altering its local environment and interaction with actin filaments. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is a tyrosine kinase inhibitor. By inhibiting tyrosine kinases that might be involved in the phosphorylation of MYO3A or associated regulatory proteins, genistein could shift the balance towards an activated state of MYO3A through reduced competitive phosphorylation. | ||||||
Sodium Orthovanadate | 13721-39-6 | sc-3540 sc-3540B sc-3540A | 5 g 10 g 50 g | $49.00 $57.00 $187.00 | 142 | |
Sodium orthovanadate is a general inhibitor of protein tyrosine phosphatases. Inhibition of these phosphatases could lead to enhanced phosphorylation status of proteins in signaling pathways linked to actin dynamics and myosin function, possibly leading to an increase in MYO3A activity. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a specific inhibitor of PKC. Inhibition of PKC isoforms can result in altered phosphorylation states of downstream proteins involved in the regulation of the actin cytoskeleton, thereby potentially affecting MYO3A activity indirectly. | ||||||